Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Pasireotide

FDA approved · Rx

Somatostatin analog

Also known as: Signifor, Signifor Lar, SOM-230, SOM230, SOM 230, pasireotida, pasireotidum

Evidence score

95/ 100

Strong evidence

Strong, human-grade evidence

Regulatory standing. FDA-approved prescription medicine
Human trials. Backed by controlled human studies
Registered human trials. 87 registered studies on ClinicalTrials.gov, most advanced Phase 4
2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Pasireotide is a synthetic cyclic peptide that mimics the natural hormone somatostatin. It binds to several somatostatin receptor subtypes, especially subtype 5, which helps reduce the release of hormones such as ACTH from the pituitary and growth hormone. It is sold under the brand names Signifor and Signifor LAR.

What the evidence shows

Automatic summaryHuman trials

Pasireotide is FDA approved for Cushing's disease in adults who are not candidates for pituitary surgery or for whom surgery was not curative (Signifor), and for acromegaly (Signifor LAR), supported by 86 registered human trials and a large published literature. Elevated blood sugar is a well documented side effect, and uses beyond its approved indications are less established.